ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity
- PMID: 38451012
- PMCID: PMC10955225
- DOI: 10.1002/mgg3.2362
ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity
Abstract
Background: The ABCG2 421C/A polymorphism contributes significantly to the distribution and absorption of antiretroviral (ARV) regimens and is associated with the undesirable side effects of efavirenz.
Methods: To investigate this, we examined ABCG2 34G/A (rs2231137) and 421C/A (rs2231142) genetic variations in 149 HIV-infected patients (116 without hepatotoxicity, 33 with ARV-induced hepatotoxicity) and 151 healthy controls through the PCR-restriction fragment length polymorphism (PCR-RFLP) technique.
Results and discussion: The ABCG2 34GA genotype and 34A allele indicated a risk for antiretroviral therapy-associated hepatotoxicity development (p = 0.09, OR = 1.58, 95% CI: 0.93-2.69; p = 0.06, OR = 1.50, 95% CI: 0.98-2.30). The haplotype GA was associated with hepatotoxicity (p = 0.042, OR = 2.37, 95% CI: 1.04-5.43; p = 0.042, OR = 2.49, 95% CI: 1.04-5.96). Moreover, when comparing HIV patients with hepatotoxicity to healthy controls, the haplotype GA had an association with an elevated risk for the development of hepatotoxicity (p = 0.041, OR = 1.73, 95% CI: 1.02-2.93). Additionally, the association of the ABCG2 34GA genotype with the progression of HIV (p = 0.02, OR = 1.97, 95% CI: 1.07-3.63) indicated a risk for advanced HIV infection. Furthermore, the ABCG2 421AA genotype was linked to tobacco users and featured as a risk factor for the progression of HIV disease (p = 0.03, OR = 11.07, 95% CI: 1.09-270.89).
Conclusion: The haplotype GA may enhance the risk of hepatotoxicity development and its severity. Individuals with the ABCG2 34A allele may also be at risk for the development of hepatotoxicity. Additionally, individuals with an advanced stage of HIV and the ABCG2 34GA genotype may be at risk for disease progression.
Keywords: ABCG2 polymorphism; ARV‐associated hepatotoxicity; HIV patients; genetic susceptibility; haplotypes.
© 2024 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Similar articles
-
The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing.Pharmacogenomics. 2023 Feb;24(3):173-182. doi: 10.2217/pgs-2022-0160. Epub 2023 Jan 20. Pharmacogenomics. 2023. PMID: 36661065 Free PMC article. Review.
-
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.Eur J Clin Pharmacol. 2022 Feb;78(2):227-236. doi: 10.1007/s00228-021-03233-7. Epub 2021 Oct 19. Eur J Clin Pharmacol. 2022. PMID: 34668025
-
Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity.Microb Pathog. 2019 Aug;133:103544. doi: 10.1016/j.micpath.2019.103544. Epub 2019 May 20. Microb Pathog. 2019. PMID: 31121270
-
CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity.APMIS. 2017 Jun;125(6):523-535. doi: 10.1111/apm.12683. Epub 2017 Apr 3. APMIS. 2017. PMID: 28370504
-
Impact of GSTM1, GSTT1 and GSTP1 gene polymorphism and risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulation.Pharmacogenomics J. 2017 Jan;17(1):53-60. doi: 10.1038/tpj.2015.88. Epub 2015 Dec 15. Pharmacogenomics J. 2017. PMID: 26667829
References
-
- Adkins, J. C. , & Noble, S. (1998). Efavirenz. Drugs, 56(6), 1055–1064. - PubMed
-
- Ajulo, M. O. , Omole, M. K. , Moody, J. O. , Dixon‐Umo, O. T. , & Salami, O. L. (2015). Liver aminotransferases in under‐five HIV‐positive children on HAART. The African Journal of Medical Sciences, 44, 197–204. - PubMed
-
- Ankathil, R. , Azlan, H. , Dzarr, A. A. , & Baba, A. A. (2018). Pharmacogenetics and the treatment of chronic myeloid leukemia: How relevant clinically? An Update. Pharmacogenomics, 19(5), 475‐393. - PubMed
-
- Ataro, Z. , Motbaynor, B. , Weldegebreal, F. , Sisay, M. , Tesfa, T. , Mitiku, H. , Marami, D. , Teklemariam, Z. , & Shewamene, Z. (2019). Magnitude and causes of first‐line antiretroviral therapy regimen changes among HIV patients in Ethiopia: A systematic review and meta‐analysis. BMC Pharmacology and Toxicology, 20(1), 63. 10.1186/s40360-019-0361-3 - DOI - PMC - PubMed
-
- Bäckström, G. , Taipalensuu, J. , Melhus, H. , Brändström, H. , Svensson, A. C. , Artursson, P. , & Kindmark, A. (2003). Genetic variation in the ATP‐binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. European Journal of Pharmaceutical Sciences, 18(5), 359–364. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical